Meningioma epidemiology and demographics

Jump to navigation Jump to search

Meningioma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Meningioma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Interventions

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Meningioma epidemiology and demographics On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Meningioma epidemiology and demographics

All Images
X-rays
Echo and Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Meningioma epidemiology and demographics

CDC on Meningioma epidemiology and demographics

Meningioma epidemiology and demographics in the news

Blogs on Meningioma epidemiology and demographics

Directions to Hospitals Treating Meningioma

Risk calculators and risk factors for Meningioma epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Ifeoma Odukwe, M.D. [2] Haytham Allaham, M.D. [3]

Overview

The prevalence of meningioma is estimated to be 97.5 cases per 100,000 individuals in the United States. The incidence of meningioma is approximately 7.62 per 100,000 individuals in the United States. Meningiomas may appear at any age, but are most commonly noticed among patients older than 50 years of age. Females are more commonly affected with meningiomas than males, with a ratio of about 2:1. Meningioma usually affects individuals of the African American race. Caucasian and Latin American individuals are less likely to develop meningioma.

Epidemiology and Demographics

Prevalence

  • The prevalence of meningioma is estimated to be 97.5 cases per 100,000 individuals in the United States. There are over 170,000 diagnosed cases in the United States.[1]
  • It was the most reported primary brain and central nervous system tumor in the Unites States between 2002 and 2006. It accounted for about 33.8% of the tumors reported, making it the most frequently diagnosed brain tumor.[1]
  • Meningioma is the second most common primary brain tumor worldwide.[2]

Incidence

  • The incidence of meningiomas annually is approximately 7.62 per 100,000 individuals in the United States. The incidence of benign meningiomas is about 7.18, about 0.32 for borderline malignant meningiomas, and about 0.12 for malignant meningiomas.[3]

Age

  • Meningiomas can occur at any age but is mostly seen with advancing age. [3]
  • It is commonly seen between the ages of 40 to 60 and is more common in postmenopausal women.[4]
  • In childhood and adolescence, meningiomas account for about 1.5% of brain tumors.[5]

Gender

  • Females are more commonly affected with meningiomas than males.[1]
  • The female to male ratio is approximately 2 to 1.
  • The incidence of meningioma among females is approximately 8.36 per 100,000 individuals in the United States, with that of males being 3.61 per 100,000 individuals.[1]
  • The female to male ratio of meningiomas may be inverted among affected patients who are younger than 15 years of age.[1]
  • Atypical and malignant meningiomas have a slight male predominace.[1]

Race

  • Meningioma usually affects individuals of the black race. Caucasian and Latin American individuals are less likely to develop meningioma.[1]

References

  1. 1.0 1.1 1.2 1.3 1.4 1.5 1.6 Wiemels J, Wrensch M, Claus EB (2010). "Epidemiology and etiology of meningioma". J Neurooncol. 99 (3): 307–14. doi:10.1007/s11060-010-0386-3. PMC 2945461. PMID 20821343.
  2. Chamberlain MC, Barnholtz-Sloan JS (2011). "Medical treatment of recurrent meningiomas". Expert Rev Neurother. 11 (10): 1425–32. doi:10.1586/ern.11.38. PMID 21955199.
  3. 3.0 3.1 Dolecek TA, Dressler EV, Thakkar JP, Liu M, Al-Qaisi A, Villano JL (2015). "Epidemiology of meningiomas post-Public Law 107-206: The Benign Brain Tumor Cancer Registries Amendment Act". Cancer. 121 (14): 2400–10. doi:10.1002/cncr.29379. PMID 25872752.
  4. Gurcay AG, Bozkurt I, Senturk S, Kazanci A, Gurcan O, Turkoglu OF; et al. (2018). "Diagnosis, Treatment, and Management Strategy of Meningioma during Pregnancy". Asian J Neurosurg. 13 (1): 86–89. doi:10.4103/1793-5482.181115. PMC 5820904. PMID 29492130.
  5. Sumkovski R, Micunovic M, Kocevski I, Ilievski B, Petrov I (2019). "Surgical Treatment of Meningiomas - Outcome Associated With Type of Resection, Recurrence, Karnofsky Performance Score, Mitotic Count". Open Access Maced J Med Sci. 7 (1): 56–64. doi:10.3889/oamjms.2018.503. PMC 6352459. PMID 30740161.